Loading
Zimberelimab is a PD-1 antibody approved in China in 2021 for relapsed classical Hodgkin lymphoma, and the checkpoint partner in Arcus and Gilead's Western trials of the TIGIT antibody domvanalimab.
Guangzhou Gloria Biosciences' zimberelimab (GLS-010) received NMPA approval in 2021 for relapsed or refractory classical Hodgkin lymphoma after at least two lines of therapy, with a later cervical cancer indication. Outside China, Arcus Biosciences licensed it as AB122 and uses it as the PD-1 backbone with domvanalimab in the STAR-121 and STAR-221 phase 3 trials in lung and gastro-oesophageal cancer. A phase 3 trial in cervical cancer is registered in China.
Blocks PD-1 on T cells so tumour cells cannot switch them off through PD-L1. Connects to PD-1.
1.Zimberelimab binds PD-1.
Compare all products across the US, EU, UK, Japan, China and Australia →
| Region | Year | Indication |
|---|---|---|
| CN | 2021 | Relapsed or refractory classical Hodgkin lymphoma after two or more lines of therapy |
Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.
Query for this drug: (TITLE:"Zimberelimab" OR ABSTRACT:"Zimberelimab" OR TITLE:"GLS-010" OR ABSTRACT:"GLS-010" OR TITLE:"AB122" OR ABSTRACT:"AB122") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about Zimberelimab, not a curated reading list.
Shares A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies, Study of Novel Treatment Combination Therapies in Participants With Head and Neck Squamous Cell Carcinoma Regardless of PD-L1 Expression Status; Subst, Study With Various Immunotherapy Treatments in Participants With Lung Cancer, Study of Novel Treatment Combinations in Patients With Lung Cancer and the tag pipeline.
Shares A Safety and Efficacy Study of Treatment Combinations With and Without Chemotherapy in Adult Participants With Advanced Upper Gastrointestinal Tract Malignancies, Study With Various Immunotherapy Treatments in Participants With Lung Cancer, Arcus Biosciences and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares PD-1, Cervical cancer and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Cervical cancer, Immune checkpoint inhibitors and the tag pipeline.
Shares Hodgkin lymphoma, Immune checkpoint inhibitors and the tag pipeline.